DrugPatentWatch Database Preview
Abatacept - Biologic Drug Details
Summary for abatacept
| Tradenames: | 1 |
| Patents: | 68 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for abatacept |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for abatacept |
Recent Clinical Trials for abatacept
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Juvenile Diabetes Research Foundation | Early Phase 1 |
| Medical College of Wisconsin | Early Phase 1 |
| Carla Greenbaum, MD | Early Phase 1 |
Recent Litigation for abatacept
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Celgene Corporation v. Aurobindo Pharma Limited | 2018-07-06 |
| CELGENE CORPORATION v. EMCURE PHARMACEUTICALS LTD. | 2018-06-28 |
| CELGENE CORPORATION v. SANDOZ INC. | 2018-06-26 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| Crescendo Bioscience, Inc | 2017-04-12 |
Pharmacology for abatacept
| Ingredient-type | Recombinant Fusion Proteins |
| Physiological Effect | Decreased Cytokine Activity |
Patent Text Search: US Patents for abatacept
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | ORENCIA | abatacept | INJECTABLE; IV (INFUSION) | 125118 | 001 | 2005-12-23 | Start Trial | Genentech, Inc. (South San Francisco, CA) | 2025-05-20 | RX | search | |
| Bristol Myers Squibb | ORENCIA | abatacept | INJECTABLE; IV (INFUSION) | 125118 | 001 | 2005-12-23 | Start Trial | Chelsea Therapeutics, Inc. (Charlotte, NC) | 2024-09-08 | RX | search | |
| Bristol Myers Squibb | ORENCIA | abatacept | INJECTABLE; IV (INFUSION) | 125118 | 001 | 2005-12-23 | Start Trial | Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) | 2026-06-02 | RX | search | |
| Bristol Myers Squibb | ORENCIA | abatacept | INJECTABLE; IV (INFUSION) | 125118 | 001 | 2005-12-23 | Start Trial | The Board of Trustees of the University of Illinois (Urbana, IL) | 2021-02-15 | RX | search | |
| Bristol Myers Squibb | ORENCIA | abatacept | INJECTABLE; IV (INFUSION) | 125118 | 001 | 2005-12-23 | Start Trial | Auspex Pharmaceuticals (La Jolla, CA) | 2028-11-12 | RX | search | |
| Bristol Myers Squibb | ORENCIA | abatacept | INJECTABLE; IV (INFUSION) | 125118 | 001 | 2005-12-23 | Start Trial | Teva Pharmaceuticals Industries, Ltd. (Petach-Tikva, IL) | 2028-09-03 | RX | search | |
| Bristol Myers Squibb | ORENCIA | abatacept | INJECTABLE; IV (INFUSION) | 125118 | 001 | 2005-12-23 | Start Trial | ForSight Vision4, Inc. (Menlo Park, CA) | 2029-01-29 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for abatacept
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Brazil | PI0913518 | Start Trial |
| Canada | 2922732 | Start Trial |
| South Korea | 20120107919 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2013120497 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2015104563 | Start Trial |
| China | 102746305 | Start Trial |
| European Patent Office | 1888106 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for abatacept
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 01730049 | Spain | Start Trial | PRODUCT NAME: SARILUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/17/1196; DATE OF AUTHORISATION: 20170623; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1196; DATE OF FIRST AUTHORISATION IN EEA: 20170623 |
| 2015 00021 | Denmark | Start Trial | PRODUCT NAME: IBRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 20141023 |
| 2017000015 | Germany | Start Trial | PRODUCT NAME: IBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945-C(2015)4704 20150703 |
| 0728 | Netherlands | Start Trial | DETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), SAMENVOEGEN |
| 0170010 00272 | Estonia | Start Trial | PRODUCT NAME: IBRUTINIIB;REG NO/DATE: EU/1/14/945 23.10.2014 |
| 17C/054 | Belgium | Start Trial | PRODUCT NAME: KEVZARA - SARILUMAB; AUTHORISATION NUMBER AND DATE: EU/1/17/1196 20170627 |
| 2017000101 | Germany | Start Trial | PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 20170623 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
